Women's Health - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 50 pages report, published by Global Markets Direct

Keywords : Women's Health Therapeutic Products under Development, Key Players in Women's Health Therapeutics, Women's Health Pipeline Overview, Women's Health Pipeline, Women's Health Pipeline Assessment

Report ThumbnailSeptember-2013
Women's Health - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Women's Health - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Women's Health, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women's Health. Women's Health - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Women's Health.
- A review of the Women's Health products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Women's Health pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Women's Health.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Women's Health pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Women's Health, H2 2013 8
  • Products under Development for Women's Health - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 11
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Discovery and Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Route of Administration, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Molecule Type, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 28
  • List of Tables
  • Number of Products Under Development for Women's Health, H2 2013 8
  • Products under Development for Women's Health - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Number of Products under Investigation by Universities/Institutes, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • GlaxoSmithKline plc, H2 2013 18
  • Neurocrine Biosciences, Inc., H2 2013 19
  • GeneScience Pharmaceuticals Co., Ltd., H2 2013 20
  • Intra-Cellular Therapies, Inc., H2 2013 21
  • Zylera Pharmaceuticals, H2 2013 22
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 28
  • Women's Health Therapeutics - Drug Profile Updates 41
  • Women's Health Therapeutics - Dormant Products 42
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Women's Health Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Women's Health 8
  • Women's Health Therapeutics under Development by Companies 10
  • Women's Health Therapeutics under Investigation by Universities/Institutes 11
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Discovery and Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Women's Health Therapeutics - Products under Development by Companies 16
  • Women's Health Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Women's Health Therapeutics Development 18
  • GlaxoSmithKline plc 18
  • Neurocrine Biosciences, Inc. 19
  • GeneScience Pharmaceuticals Co., Ltd. 20
  • Intra-Cellular Therapies, Inc. 21
  • Zylera Pharmaceuticals 22
  • Women's Health - Therapeutics Assessment 23
  • Assessment by Monotherapy Products 23
  • Assessment by Combination Products 24
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 29
  • epelsiban besylate - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • cidofovir - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • leuprolide acetate - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • GnRH Antagonists - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • ZYL-3177X - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • ZYL-65987 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • NT-100 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • Women's Health Program - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • EVE-112 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • EVE-106 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • Progesterone Based Formulation For Preterm Birth - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Women's Health Therapeutics - Drug Profile Updates 41
  • Women's Health Therapeutics - Dormant Products 42
  • Women's Health - Product Development Milestones 43
  • Featured News & Press Releases 43
  • Aug 20, 2013: Florida Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures 43
  • Sep 07, 2011: Repros Reports Interim Data From Phase III Study Of Low Dose Oral Proellex 43
  • Jul 19, 2010: Gilead Sciences Announces Results From Clinical Trial Of Tenofovir Gel For Women's HIV Prevention 44
  • Jun 25, 2010: Merck Challenges Verdict in Federal FOSAMAX (alendronate sodium) Trial 45
  • Jun 07, 2010: Statement on FOSAMAX (alendronate sodium) Product Liability Trial in U.S. District Court 46
  • May 06, 2010: Swedish Orphan Biovitrum Presents First Positive Kiobrina Clinical Phase II Data 46
  • May 05, 2010: Merck Wins Second Federal FOSAMAX (alendronate sodium) Bellwether Trial 47
  • Nov 23, 2009: Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX (alendronate sodium) 47
  • Sep 11, 2009: Mistrial Declared in First Federal FOSAMAX Trial 48
  • Sep 10, 2009: Pantarhei Bioscience Has Organised A Symposium At This Congress Of The European Society Of Gynecology, Rome, Italy 48
  • Appendix 49
  • Methodology 49
  • Coverage 49
  • Secondary Research 49
  • Primary Research 49
  • Expert Panel Validation 49
  • Contact Us 50
  • Disclaimer 50

Please select a license type

Share

Related Products

Global Markets DirectWomen's Health - Pipeline Review, H2 2013Product ThumbnailWomen's Health - Pipeline Review, H2 2013, Industry ReportProduct #: 113340
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved